ACCC raises concerns about iNova weight loss pharma deal

The ACCC has raised preliminary concerns that iNova’s proposed acquisition of pharmaceutical developer Juno PC would ‘limit competition in the market for weight loss medication’.

Submissions on the statement of issues can be made until 7 February with a final decision scheduled for 9 April 2020.

View media release.

View merger register.